Videos

Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.

Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.

Arvind Dasari, MD, examines the progression-free survival and overall survival data from the FRESCO-2 trial, comparing the results to the original FRESCO trial, and discussing the implications for the treatment of heavily pretreated metastatic colorectal cancer patients.

Dr. Kuykendall provides his perspective on the biggest unmet needs with current advanced PV therapies, emerging data he is following that may impact future management, and any other clinical pearls for optimal PV management.

Dr. Kuykendall discusses the important quality of life aspects to consider when treating PV patients and the specific strategies or treatments he uses to help preserve overall QoL throughout the disease course.

Dr. Kuykendall explains how he monitors PV patients for thrombosis risk, which hematological values concern him most, and his approach if hematocrit rises above 45%.

Dr. Kuykendall shares his experience using peginterferon or ropeginterferon for PV treatment, including the biggest challenges, limitations, and managing safety/tolerability issues with these agents.

Dr. Kuykendall discusses the efficacy and safety findings from studies like MAJIC-PV and PROUD-PV, and how they influence his treatment choices for PV.

Dr. Kuykendall comments on the high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in the RESPONSE trial for hydroxyurea-resistant/intolerant PV, and how these efficacy findings inform his treatment choices.

Dr. Kuykendall explains the factors he considers when deciding on initial therapy for advanced PV patients, including comorbidities, individual patient factors like age and symptoms, and weighing the risks and benefits of different treatment options.

Dr. Kuykendall discusses his initial impressions of the case, how it compares to typical advanced polycythemia vera presentations, and typical risk factors seen in PV patients.

Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.

Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients' quality of life.

Dr. Bose shares his perspective on how he monitors and manages anemia for patients on ruxolitinib, including when he would consider dose reduction or transfusion.

Dr. Bose discusses when he typically initiates ruxolitinib for his intermediate- or high-risk myelofibrosis patients.

Dr. Bose reviews the efficacy and safety findings from various studies on JAK inhibitors, including JAKARTA, PERSIST-1, PERSIST-2, SIMPLIFY-1 & 2, and MOMENTUM, and how these data inform his treatment choices.

Dr. Bose discusses the key findings from the COMFORT I and II trials and how the overall survival data has impacted the way he manages patients with myelofibrosis, along with the factors that most inform his treatment decisions.

Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.

Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.

Anne O’Dea, MD, discusses factors that contribute to second-line treatment selection and offers clinical insights on improving outcomes for patients being treated for breast cancer.

Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.

Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.

A hematologist-oncologist discusses the importance of biomarker testing in breast cancer, provides clinical insights on how to prioritize different testing assays, and outlines the roles of circulating tumor DNA and repeat testing.

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin lymphoma.

Anne P. O'Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and prognosis.

Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with chronic lymphocytic leukemia.

Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease, particularly highlighting their ability to inhibit the fibrosis cascade, which offers substantial benefits for patient healing and recovery.

Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm compared to 60% in the best-available therapy arm.

Adam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.

Discussing perspectives on the future landscape of chronic GvHD management, including limitations of current targeted treatment options and emerging research of interest.